St Elizabeth Healthcare Residency in Family Medicine
Family Medicine
Dr. Mark A. Boyd, MD
|
|
Give Review
Mark Boyd practices Family Medicine. He went to medical school at University of Cincinnati College of Medicine. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Dr. Mark A. Boyd is a published physician as well. He has 43 publications published. The latest was: SPRING-2 the future of antiretroviral therapy. He is registered with Medicare and accepts Medicare payments.
Publications
- SPRING-2 the future of antiretroviral therapy.
- Antiretroviral therapy: dolutegravir sets SAIL(ING).
- Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin treated HIV/tuberculosis co-infected patients: a pilot study.
- Current and future management of treatment failure in low- and middle-income countries.
- Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
- Improvements in antiretroviral therapy outcomes over calendar time.
- Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT...
- Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efav...
- Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.
- Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.
- Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
- Operational research in HIV priority areas: the African way.
- Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.
- The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool.
- Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a...
- Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
- An unusual cause of severe metabolic acidosis.
- Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research.
- Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
- A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).
- Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-N...
- The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
- Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis.
- Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.
- Creation of a drug fund for post-clinical trial access to antiretrovirals.
- Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.
- Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
- Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
- The long-term consequences of antiretroviral therapy: a review.
- Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
- Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.
- Antiretroviral roll-out: the problem of second-line therapy.
- Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
- Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretrov...
- The Sydney Declaration: a call to scale up research.
- Pandemic influenza: clinical issues.
- Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes...
- Evidence and policy in the globalized response to AIDS.
- Considering the benefits of disease-specific interventions on overall public health.
- Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?
- Dolutegravir-a promising antiretroviral in development.
- A febrile illness with generalized papular rash involving the palms and soles.
Schools
University Of Cincinnati College Of Medicine
Naval Hospital
Doctors Specialties
- Family Medicine
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Ind Direct Access KY
- Pathway X Tiered Hosp/Ind Direct Access OH
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Choice Care PPO
- Preferred PPO
- MultiPlan PPO
- PHCS Network PPO
- Sagamore Plus
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Cincinnati College of Medicine
Drug Facts
| NPI NUMBER | 1811066178 | |
| NPPES Provider LastName | BOYD | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 410110801 | |
| NPPES Provider State | KY | |
| Specialty Description | Family Practice | |
| Total Claim Count | 1381.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 29.0 | |
| Percent Opioid Claims | 2.1 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811066178 |
| Last Name Of The Provider | BOYD |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. M T. Philippe, MD |
|
|
Dr. Patrick T. Burns, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel E. Rutterer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David F. Lowe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert T. Longshore, MD |
|
|
Dr. James R. Rich, MD |
|
|
Dr. Bradley S. Patterson, MD
This Doctor is OpenDoctor Recommended.
|